HistopathologyPaired with clinical endpoints, histopathology provides comprehensive insight for model characterization and therapeutic efficacy as you progress through the drug discovery pipeline. We offer seamless integration of these critical endpoints through our collaboration with the experts at DTR Labs.
The team at DTR provides non-clinical, non-GLP histology services guided by ACVP-board certified pathologists including:
As our preferred histopathology partner, DTR Labs provides our clients with seamless access to both BioModels’ and DTR’s services under a single work order. This collaborative approach allows for a comprehensive experience, without having to outsource histopathology/IHC to a third party.
We take care of the entire process including:
For more information on our collaboration and how we can support your preclinical study needs and endpoint analysis, please email info@biomodels.com. Click HERE to request more details on DTR Labs’ (1) MASLD/MASH Liver Analysis and (2) Colonic Collagen Quantification in a Mouse Model of DSS.
Areas of Expertise
| Fibrosis | • Colonic Fibrosis/Fibrostenosis • Dermal Fibrosis • Hepatic Fibrosis • Idiopathic Pulmonary Fibrosis • Renal Fibrosis • Systemic Sclerosis/Scleroderma |
| Oncology | • Descriptive Pathology (Differentiation and Morphology) • Regional Inflammation Quantification • Necrosis/apoptosis Quantification • Proliferation Quantification • Microvascular Density Quantification • Tumorigenesis Protein/RNA Quantification • H-scoring • Metastasis Evaluation |
| Cardiovascular Disease | • Pulmonary Hypertension • Atherosclerosis • Cardiomyopathy • Myocardial Infarction |
| Colitis | • General Assessments • Fibrostenosis • Inflammation • Carcinogenesis |
| Inflammation/Immunology | • Acute Lung Injury • Acute Hepatitis • Arthritis • Asthma • Atopic Dermatitis • Celiac Disease • Graft vs Host Disease • Multiple Sclerosis • Systemic Lupus Erythematosus |
| Metabolic Disease | • NASH/MASH • Alcoholic Liver Disease • Storage Diseases |
| Translational Research | • Human-Animal Model Integration • Novel Protein Assay Development and Analysis (Human and Animal) • Non-Clinical Human Tissue Analysis to facilitate biomarker discovery |
| Model Development | • Animal Model Support • Endpoint Selection/Characterization |
| Safety | • Toxicologic Pathology Evaluation • Follow-up Biodistribution Investigation (IHC/ISH) |
| Cell/Gene Therapy | • Efficacy Analysis • Biodistribution Quantification • Safety Evaluation |
